Etiket: Ebola

First Volunteer Receives Experimental Ebola Vaccine in Oxford!

Ed Hunt, a 37-year-old man from the UK, has made headlines as the world’s first volunteer to receive an experimental vaccine against the Ebola viru

Ed Hunt, a 37-year-old man from the UK, has made headlines as the world’s first volunteer to receive an experimental vaccine against the Ebola virus, and it all went down in Oxford. The decision to step up came after Hunt was moved by the grim news reports of the Ebola outbreak in the Democratic Republic of Congo. He had initially wanted to join the Covid vaccine trials but due to work commitments, he couldn’t. But after seeing the devastation in DR Congo, he thought, “Why not do my part?”

The vaccine, developed in a remarkably short span of just eight weeks, is built on the same technology that was used for the UK’s earlier Covid vaccine. Hunt, in an interview, emphasized that this trial won’t expose anyone to the Ebola virus. Instead, the focus is on generating a robust immune response that could potentially protect against the Bundibugyo species of Ebola.

As Hunt received the shot, it wasn’t just a personal milestone; it was a moment of hope. The UK is now taking significant steps in tackling the Ebola threat with this trial. Just recently, Uganda celebrated a ‘moment of joy’ as the last Ebola patient was discharged, signaling a possible end to their outbreak.

What’s exciting here is that this vaccine trial not only aims to protect individuals but could pave the way for broader immunization strategies against this deadly virus. The world is watching closely, and the urgency couldn’t be greater, especially with the recent surge in Ebola cases globally.

So, what do you think? Will this trial mark a turning point in the fight against Ebola? Only time will tell, and we’ll be keeping a close eye on how things unfold in the coming weeks.

Kaynak: Orijinal Haber

UK Humanitarian Worker Under Ebola Monitoring at London Hospital

A humanitarian worker from the Democratic Republic of Congo has been medically evacuated to the UK due to a possible exposure to Ebola while working

A humanitarian worker from the Democratic Republic of Congo has been medically evacuated to the UK due to a possible exposure to Ebola while working in the healthcare sector. The UK Health Security Agency (UKHSA) confirmed that the individual, a resident of the UK whose identity remains undisclosed, is currently asymptomatic. This precautionary measure is designed to ensure the safety of the public, and the worker is being monitored at a London hospital.

Now, the hospital where the worker is receiving treatment has not been disclosed, but it’s widely understood that the Royal Free Hospital in north London is the primary facility for high consequence infectious diseases in the country. This hospital is equipped with a high-level isolation unit, suitable for cases like this, and has extensive experience handling such dangerous pathogens. The worker will have to remain in isolation for the duration of the Ebola incubation period, which ranges from two to 21 days.

For those unfamiliar with Ebola, it is a highly dangerous virus that does not spread through the air like flu or Covid-19. Instead, it requires direct contact with bodily fluids to transmit, which makes understanding its spread crucial. Symptoms can often mimic those of the flu or malaria, starting with fever, headache, and fatigue. However, as the disease progresses, it can lead to severe complications such as vomiting, diarrhea, and potentially organ failure. In some cases, patients may experience internal and external bleeding.

Richard Pebody, director of epidemic and emerging infections at UKHSA, reassured the public by stating, “The risk to the general public remains low.” He expressed relief that the individual remains well, indicating that while the situation is serious, the immediate threat to the community is minimal. The humanitarian worker had been involved with an organization responding to the Ebola outbreak, illustrating the risks those in the field take to help others.

It’s important to note that the situation is continuously evolving. As more details emerge, the UKHSA and health officials will keep the public informed. The world has seen the devastating impact of Ebola outbreaks in the past, and with every case, there are lessons learned from survivors and experts in the field. Recovery stories provide a glimmer of hope even in the darkest times, showcasing the resilience of the human spirit amidst outbreaks.

As we follow this developing story, one can’t help but wonder: How will the public health response adapt to ensure safety while continuing to support humanitarian efforts? It remains to be seen what additional measures will be implemented as the monitoring continues.

Kaynak: Orijinal Haber

UK Launches Urgent Trials for Rapidly Developed Ebola Vaccine

A new Ebola vaccine is set to enter human trials after being given the green light by UK regulators. Scientists from the University of Oxford kicked

A new Ebola vaccine is set to enter human trials after being given the green light by UK regulators. Scientists from the University of Oxford kicked off the development just eight weeks ago, following a public health emergency declaration on May 17. This vaccine is the first of four in development to reach this critical stage. Right now, they’re looking for volunteers, with the first doses expected to be administered to healthy adults in the UK “within weeks.”

The trial will involve 50 healthy adults aged between 18 and 55. Meanwhile, researchers are teaming up with partners in Uganda to lay the groundwork for trials in Africa, where the need for effective vaccines is crucial. Volunteers will be closely monitored for an entire year. However, scientists anticipate being able to determine relatively quickly whether the vaccine can trigger the desired immune response or if it produces any unexpected side effects.

What’s exciting is how the Oxford team managed to whip up this vaccine in such a short time – they’re utilizing the same tech that gained fame during the Covid pandemic, specifically the platform used for the Oxford/AstraZeneca Covid vaccine. This innovative approach employs a common cold virus that infects chimpanzees, which has been genetically modified to ensure it’s safe. Think of it like sending a letter in an envelope – the researchers just need to swap out the message inside before delivering it to the body. For Covid, that message was a snippet of the virus’s genetic code.

Now, the Medicines and Healthcare Products Regulatory Agency has officially approved the commencement of human trials. Vaccine researcher Alex Sampson shared with the BBC that typically, vaccines can take up to a decade to research, develop, and prove effective. However, he emphasizes that no corners are being cut, stating, “We are able to do them in parallel, so it means a lot of teams working in lots of different places around the clock, but we’re still doing everything that we would normally do.”

He also stressed the importance of safety, reminding everyone that the Covid AstraZeneca vaccine was given to millions of people without issues. In a heartfelt moment, he reflected on his personal loss, saying, “I buried my parents one day after the other.”

The urgency behind this trial is palpable, and one can’t help but wonder how quickly we might see results. Will this vaccine be able to fend off the deadly Ebola virus effectively? Only time will tell…

Kaynak: Orijinal Haber

UK Scientists Race Against Time to Develop Ebola Vaccine Amid Outbreak

Scientists at Oxford University are in a race against time, working on a new Ebola vaccine that could be ready for clinical trials in just two to thr

Scientists at Oxford University are in a race against time, working on a new Ebola vaccine that could be ready for clinical trials in just two to three months. This urgent effort comes as the outbreak in the Democratic Republic of Congo has escalated alarmingly, with 750 suspected cases and 177 deaths reported. The strain of Ebola they’re targeting, known as Bundibugyo, is particularly deadly, killing approximately one-third of those it infects and, crucially, there’s currently no proven vaccine for it.

Now, the situation is looking quite serious. The World Health Organization (WHO) has raised the risk level from “high” to “very high” in the affected areas of Congo, and while the broader region also faces a high risk, globally the threat remains low. This escalation follows the WHO’s declaration of a public health emergency of international concern, emphasizing that this outbreak is not yet a pandemic.

Interestingly, another experimental vaccine for Bundibugyo is being developed, but it may take six to nine months before it’s ready for testing. The vaccine being crafted by the Oxford team employs the same technology they used during the Covid pandemic. This adaptable technology, referred to as ChAdOx1, can be quickly modified to combat different infections. Previously, it was infused with genetic material from the Covid virus, but now it’s been re-engineered using genetic information from the Bundibugyo strain of Ebola.

This innovative vaccine uses a common cold virus that usually infects chimpanzees, but it’s been modified to ensure safety for humans. By utilizing this altered cold virus, researchers can deliver critical genetic material about the Bundibugyo virus to human cells, effectively training the immune system to recognize and combat the actual disease without causing any infection or Ebola symptoms.

However, there’s a catch. The WHO has pointed out that there isn’t any animal data yet to bolster the effectiveness of this specific vaccine. A spokesperson mentioned, “It is possible that doses of that could be available for clinical trial in two to three months, but there is a lot of uncertainty.” The effectiveness will hinge on the results of ongoing animal trials, which are reportedly underway in Oxford.

Once the vaccine is ready for mass production, the Serum Institute of India is set to step in and help produce it on a large scale, pending the delivery of medical-grade materials from Oxford. Professor Lambe, who heads the Vaccine Immunology department at the Oxford Vaccine Group, emphasized the need for speed, stating, “Once we get starting material to them they can go fast and they can go big.”

As for the current outbreak, it’s proving to be quite challenging due to the rarity of the Bundibugyo strain. Among the six species of the Ebola virus, only three are known to cause significant outbreaks. Bundibugyo has a limited history, with just two previous outbreaks documented—one in Uganda in 2007 and another in DR Congo in 2012. In fact, it hasn’t been seen for over a decade. While vaccines are available for the more common Zaire strain, the Bundibugyo strain remains without a proven vaccine.

It’s important to note that, unlike the mass vaccination efforts during the Covid pandemic, Ebola vaccines will be administered using a method called ring vaccination. This means only those individuals who are most at risk, including close contacts of Ebola cases and healthcare workers treating infected patients, will be immunized.

The Oxford team has been diligently working on similar vaccines for other strains of Ebola and even the Marburg virus. They might have caught this rare strain before the outbreak was officially recognized, according to reports from the Red Cross.

As the race continues to develop this critical vaccine, one can’t help but wonder how effective it will be and what the next steps will be if this outbreak escalates further. The world watches closely…

Kaynak: Orijinal Haber

Ebola Outbreak Risk Soars to ‘Very High’ in DR Congo: What You Need to Know

The World Health Organization (WHO) has raised the public health risk from the ongoing Ebola outbreak in the Democratic Republic of Congo (DRC) from

The World Health Organization (WHO) has raised the public health risk from the ongoing Ebola outbreak in the Democratic Republic of Congo (DRC) from “high” to “very high.” This alarming update was shared by WHO chief Dr. Tedros Adhanom Ghebreyesus on Friday. He pointed out that while the risk remains “low” globally, the situation in the wider African region is deemed “high.”

Now, let’s get to the heart of the matter. This outbreak is caused by a rare species of Ebola known as Bundibugyo, which tragically has no proven vaccine available and a mortality rate that sees about one-third of those infected losing their lives. To date, the outbreak has claimed 177 suspected lives and has seen approximately 750 suspected cases in the DRC. Yahu, that’s a lot of suffering for the people there.

Meanwhile, scientists at Oxford University in the UK are racing against time to develop a new vaccine that could potentially enter clinical trials in just two to three months. This vaccine is based on the same technology that was utilized for the AstraZeneca Covid vaccine, but there are no guarantees it will be effective. Animal research is already underway, and they’re hopeful. The Serum Institute of India is ready to mass-produce the Ebola vaccine once they receive the necessary medical-grade materials from Oxford.

But wait, there’s more. Another experimental vaccine specifically for Bundibugyo is also on the drawing board, but it’s projected to take six to nine months before it’s ready for testing. Dr. Vasee Moorthy, WHO’s research and development adviser, has described this vaccine as “the most promising” and likened it to Ervebo, which is already used for the more common Zaire species of Ebola.

In a recent briefing in Geneva, Dr. Tedros shared some sobering statistics: 82 confirmed cases and seven confirmed deaths in the DRC. He also mentioned that the situation in neighboring Uganda, where two confirmed cases and one death have been recorded, is currently stable, with both cases traced back to travel from the DRC. It’s scary to think about how quickly this virus can spread.

Ebola is a rare but deadly disease, primarily infecting animals such as fruit bats, but it can jump to humans, often starting when people consume or handle infected animals. On Sunday, the WHO declared a public health emergency of international concern, but thankfully, it’s not at pandemic levels just yet. However, Dr. Tedros emphasized the importance of building trust within the communities affected, warning that violence and instability in the war-torn region are making it tougher to respond effectively to the outbreak.

In fact, some Ebola cases have been confirmed in rebel-held areas, which adds another layer of complexity to an already dire situation. Following a tragic incident where angry relatives set fire to a hospital in eastern DRC—because health workers refused to release the body of a patient due to contamination risks—local politician Luc Malembe Malembe described the chaos: “They started throwing projectiles at the hospital… They even set fire to tents that were being used as isolation wards.” It’s heartbreaking to see that in the midst of a health crisis, fear and anger can lead to such violent outbursts.

The body of an Ebola victim is highly infectious, and authorities stress the importance of safe burial practices to prevent the virus from spreading further. Medical staff at the hospital, located near Bunia in Ituri province—where the majority of cases have been reported—were placed under military protection as police moved in to restore order. The fear is palpable in these Ebola-stricken areas; a young taxi rider in Rwampara expressed his dread, saying, “I am scared because people are dying very fast… we are really afraid.”

Fred Kiza, another local resident, echoed this sentiment, highlighting that such fear is “normal when there’s a disease like this.”

So, what’s next? Will the vaccine trials bring hope, or will the outbreak continue to spiral? The community is holding its breath, hoping for a breakthrough that could end this nightmare. Gelişmeleri takip ediyoruz…

Kaynak: Orijinal Haber